🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07311369
Recruiting Phase 2

Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Pain Management in Abdominal Surgery

NCT07311369 · tracked via the Priya Life Science China tracker
Sponsor
Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
Phase
Phase 2
Started
2025-12
Last updated
2025-12-30

Condition(s) studied

Moderate to Severe Acute Postoperative Pain

Investigational drug(s) / intervention(s)

HL-1186HL-1186 placebo

HL-1186: HL-1186 tablet for oral administration.

HL-1186 placebo: HL-1186 placebo tablet for oral administration.

Study summary

This is a multiple-center, randomized, double-blind, placebo-controlled study design evaluating the safety, efficacy, and pharmacokinetics (PK) parameter of HL-1186 tablet for postoperative pain management in abdominal surgery.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: 1. 18 years old ≤ age ≤ 75 years old, gender is not limited. 2. 18 kg/m2 ≤ Body Mass Index (BMI) ≤ 30kg/m2. 3. Scheduled to undergo abdominal surgeries under general anesthesia. 4. Able to understand the research process and the use of pain scales, and communicate effectively with researchers. Exclusion Criteria: 1. Prior history of surgery at the same site, and this may affect pain perception at the surgical site per investigator's judgments. 2. Allergy to any component of the investigational product, to perioperative anesthetic/analgesic/antiemetic agents, or to ≥3 substance allergies. 3. Unstable angina, myocardial infarction, severe arrhythmias (e.g., third-degree atrioventricular block), New York Heart Association (NYHA) class III or higher cardiac function, recurrent asthma, etc., within screen period, and deemed ineligible per investigator's judgments. 4. High bleeding risk conditions: Congenital bleeding disorders (e.g., hemophilia), platelet function abnormalities (e.g., idiopathic thrombocytopenic purpura, disseminated intravascular coagulation, congenital platelet function abnormalities), active bleeding, etc., and deemed ineligible per investigator's judgments. 5. For female participants: Pregnant or lactating (within 1 year postpartum). 6. Participants with childbearing potential planning conception/sperm/egg donation within 6 months post-treatment, or unwilling to use effective contraception (abstinence, barrier methods, oral contraceptives, intrauterine device, or sterilization). 7. Judgment by the investigator that the participant should not enter the study due to other conditions.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
The Third Xiangya Hospital of Central South University Changsha Hunan Recruiting

More Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07311369 on ClinicalTrials.gov ↗ ← All trials in China